Pulse Biosciences, Inc. (PLSE)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
$53.07-6.99%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
QuarterlyIQ Insights · PLSE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -6.1% |
| Our one-year growth estimate | diamond | Not available |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 15 industry peers
PLSE — debt issuance
Dated 2026-09-15
Entry into a Material Definitive Agreement. On September 15, 2026, Pulse Biosciences, Inc. (the “Company”) entered into an equity distribution agreement (the “Sales Agreement”) with Mizuho Securities USA LLC (“Mizuho”) as sales agent, pursuant to which the Company may offer and sell, from time to time, through Mizuho, shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $85,000,000 (the “Shares”). The Company is not…
Why it matters: The center is treating patients and plans to gather real-world results. Patient use and data can show whether the thyroid launch is gaining traction.
Supportive ifThe center says it is treating patients and shares thyroid results that can be measured through the partnership.
Worry ifA company update says patient treatment or outcome data have not begun. Or, the partnership has ended.
Why it matters: Management targeted enrollment completion by early Q4, even after raising the goal to 164 patients. A clear update will test that timeline.
Supportive ifThe company confirms all 164 patients are enrolled and gives a date for the next trial update.
Worry ifEnrollment is still incomplete after early Q4. Or, the company delays the next trial update without giving a new date.
Why it matters: Q2 operating cash use was $18.7 million, and the company has new stock-sale capacity. Lower cash use can ease funding pressure; more share sales can dilute owners.
Watch forQ3 operating cash use is below $18.7 million, with no new shares sold through the sales agreement.
Also watch forQ3 operating cash use is above $18.7 million. The company also reports selling more shares through its sales agreement.
Why it matters: The company reported $434,000 in Q2 revenue during a controlled launch. Higher sales would show more use; flat or lower sales would show slow uptake.
Watch forQ3 revenue is above $434,000. The company also reports more procedures or repeat use.
Also watch forQ3 revenue is $434,000 or less. Or, the company reports fewer procedures or repeat users.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$252 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $615 loss on $10,000 · 6.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,950 loss on $10,000 · 29.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.